 |
answer text |
<p>The UK Government recognises that the Global Tuberculosis Report 2019 provides
important evidence on the challenges in tackling tuberculosis as an issue of global
public health importance. It shows that progress has been made, particularly improvements
in the number of cases of tuberculosis identified and increases in testing coverage
for drug resistant tuberculosis. 7 million people with tuberculosis were identified
globally in 2018; 600,000 more people than in 2017. Additionally, the proportion of
people with a tuberculosis diagnosis who were tested for drug resistance rose from
41% in 2017 to 51% in 2018.</p><p> </p><p>Investments in the Global Fund have played
a major role in tackling the global epidemic of tuberculosis. Dealing with drug resistant
tuberculosis is a key focus of the Global Fund through prevention, detection and treatment,
including supporting countries to introduce bedaquiline and delamanid, two ground
breaking new drugs for the treatment of drug-resistant tuberculosis. The new drugs
have fewer side effects and are more effective, increasing the chances that people
will stay on the treatment and be cured.</p><p> </p><p>We work with the Global Fund
to ensure that our investment continues to support advances to improve access to treatment
for both drug sensitive and drug resistant tuberculosis.</p>
|
|
